You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《新股消息》药明巨诺(02126.HK)今日起招股 入场费12,019.92元
阿思达克 10-22 09:27
由药明康德(02359.HK)及美国医药研发平台Juno共同投资、内地临床及临床前阶段细胞治疗公司药明巨诺(02126.HK)公布招股详情,计划发行9,769.2万股,当中约10%在港公开发售,招股价介乎20至23.8元,一手500股,入场费12,019.92元;由今日(22日)至下周三(28日)公开招股,预计11月3日挂牌上市。高盛及瑞银为联席保荐人。

该股引入10名基石投资者,共认购1.5亿美元股份,包括Rock Springs Capital、橡树资本管理公司等各认购2,000万美元;高瓴基金、太平资产管理等各认购1,000万美元。

以招股价中位数21.9元计,公司预计集资净额为20.18亿元,当中30%将用於有关relma-cel的研发活动;10%用於建立专门的内部销售与营销团队将relmacel推广至中国各地;6%用於有关JWCAR129的研发活动;28%用於有关其他临床前候选产品;4%用於透过行使Acepodia选择权获得Acepodia许可;12%将用於新潜在收购及引进授权机会;余下10%为营运资金及一般公司用途。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account